Hua Medicine
02552
Company Profile
Business description
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from PRC.
Contact
Lane 36, Xuelin Road
Hua Medicine, Building 2
Pudong New Area
Shanghai201203
CHNT: +86 2138101800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
285
Stocks News & Analysis
stocks
Are investors too bearish on Australian equities?
A new report suggests the pessimism might be overdone.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.60 | 30.70 | 0.33% |
| CAC 40 | 8,200.88 | 15.70 | -0.19% |
| DAX 40 | 24,124.21 | 154.42 | -0.64% |
| Dow JONES (US) | 47,632.00 | 74.37 | -0.16% |
| FTSE 100 | 9,756.14 | 59.40 | 0.61% |
| HKSE | 26,482.22 | 136.08 | 0.52% |
| NASDAQ | 23,958.47 | 130.98 | 0.55% |
| Nikkei 225 | 51,271.60 | 36.05 | -0.07% |
| NZX 50 Index | 13,480.86 | 71.65 | 0.53% |
| S&P 500 | 6,890.59 | 0.30 | -0.00% |
| S&P/ASX 200 | 8,911.30 | 31.30 | 0.35% |
| SSE Composite Index | 4,010.23 | 6.10 | -0.15% |